...
首页> 外文期刊>Cell biochemistry and function >Alterations in circulating angiogenic and anti-angiogenic factors in type 2 diabetic patients with neuropathy
【24h】

Alterations in circulating angiogenic and anti-angiogenic factors in type 2 diabetic patients with neuropathy

机译:2型糖尿病患者神经病变患者血管生成和抗血管生成因子的改变

获取原文
获取原文并翻译 | 示例

摘要

Diabetic peripheral neuropathy (DPN) is one of the most common diabetic chronic complications. There is an increased attention directed towards the role of angiogenic factors including vascular endothelial growth factor (VEGF) and anti-angiogenic factors including soluble endoglin (sEng) as contributors to diabetic microvascular complications including neuropathy. The purposes of this study were to determine the role of these angiogenesis regulators in the prognosis of DPN. The study group included 60 patients with type 2 diabetes mellitus (T2DM) and 20 clinically healthy individuals. The patients were divided into two groups. Group I included 20 T2DM patients without peripheral neuropathy, and Group II consisted of 40 T2DM patients with DPN. In all groups, plasma VEGF, sEng and endothelin-1 (ET-1), nitric oxide and ET-1 mRNA were estimated. Plasma levels of VEGF, sEng, ET-1 and nitric oxide were significantly elevated in diabetic patients (Groups I and II) compared with healthy control subjects, with a higher increase in their levels in patients with DPN compared with diabetic patients without peripheral neuropathy. Measurement of plasma levels of angiogenesis-related biomarkers in high-risk diabetic patients might identify who later develop DPN, thus providing opportunities for early detection and targets for novel treatments.
机译:糖尿病外周神经病变(DPN)是最常见的糖尿病慢性并发症之一。血管生成因子(包括血管内皮生长因子(VEGF)和抗血管生成因子,包括可溶性endoglin(seng)作为糖尿病微血管并发症,包括神经病变的贡献者的作用。本研究的目的是确定这些血管生成调节剂在DPN预后的作用。该研究组包括60例患有2型糖尿病(T2DM)和20名临床健康个体患者。患者分为两组。群体包括20个T2DM没有周围神经病变的患者,第II组由40个T2DM患者组成。在所有基团中,估计等离子体VEGF,Seng和内皮素-1(ET-1),一氧化氮和ET-1 mRNA。与健康对照受试者相比,糖尿病患者(Ⅰ组和II族)在糖尿病患者(Ⅰ组和II)中显着升高了VEGF,Seng,ET-1和一氧化氮的血浆水平,与没有周围神经病变的糖尿病患者,DPN患者的水平较高。测量高风险糖尿病患者中血管生成相关生物标志物的血浆水平可能识别后来发展DPN,从而为新型治疗提供早期检测和靶标的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号